Effect of single or combined treatment of naproxen, acetaminophen and omega- 3 on Knee osteoarthritis

Effect of single or combined treatment of naproxen, acetaminophen and omega -3 on Knee osteoarthritis in 45-65 years old persons

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012102610799N2

Enrollment

210

Registered

2013-05-30

Start date

2013-02-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis. Gonarthrosis [arthrosis of knee],Primary gonarthrosis, bilateral

Interventions

Intervention 1: The first group receive acetaminophen(1000milligram(mg),q8h) for 6 weeks. Intervention 2: The second group receive naproxen(500 mg,q12h) for 6 weeks. Intervention 3: The third group

Treatment - Drugs

The first group receive acetaminophen(1000milligram(mg),q8h) for 6 weeks.

The second group receive naproxen(500 mg,q12h) for 6 weeks.

The third group receive naproxen(500 mg,q12h) and Omega-3(1000 mg,q8h) for 6 weeks.

The fourth group receive acetaminophen(1000 mg,q8h) and Omega-3(1000 mg,q8h) for 6 weeks.

The fifth group receive acetaminophen(1000 mg,q8h) and naproxen(500 mg,q12h) for 6 weeks.

The sixth group receive acetaminophen(1000 mg,q8h) ,naproxen(500 mg,q12h) and omega-3(1000 mg,q8h)for 6 weeks.

Eligibility

Sex/Gender

All

Age

45 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria include idiopathic knee osteoarthritis in 45-65 years persons old with mild to moderate knee pain. Exclusion criteria include rheumatic arthritis, septic arthritis, previous joint trauma, acute joint trauma, old fractures of joint, joint anomalies, alcohol abuse, hepatic insufficiency, heparin use, steroid use during 2 months ago, steroid or hyalgan injection into the joint during 9 months ago, taking oral steroid in 8 days ago, gastrointestinal bleeding, renal insufficiency, pregnancy or lactation woman, hypersensitivity to remember drugs, severe respiratory insufficiency and knee prosthesis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

Measure	Time frame
Pain. Timepoint: After end of intervention(6 weeks after start of intervention). Method of measurement: Visual analogue scale.;Joint stiffness. Timepoint: After end of treatment. Method of measurement: WOMAC.;Physical functions. Timepoint: After end of treatment. Method of measurement: WOMAC.;Pain. Timepoint: After end of treatment. Method of measurement: Visual analogue scale.	—

Primary

Measure	Time frame
Pain. Timepoint: Before starting of intervention. Method of measurement: Visual analogue scale.;Joint stiffness. Timepoint: Before treatment. Method of measurement: WOMAC.;Physical functions. Timepoint: Before treatment. Method of measurement: WOMAC.;Pain. Timepoint: Before treatment. Method of measurement: WOMAC.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAshkan Arjemand

Yasuj University of Medical Sciences

Ashkan.arjemand2@yahoo.com+98 74 1223 0290

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026